|
|||||
|
|
| 伊立替康联合奥沙利铂治疗广泛期小细胞肺癌的临床观察 | |
| 引用本文： | 李海金,董良,李英,陈亚男,尚官敏. 伊立替康联合奥沙利铂治疗广泛期小细胞肺癌的临床观察[J]. 中华肿瘤防治杂志, 2010, 17(3) |
| 作者姓名： | 李海金 董良 李英 陈亚男 尚官敏 |
| 作者单位： | 中国医科大学绍兴医院肿瘤内科,浙江,绍兴,312030 |
| 摘 要： | 目的:观察伊立替康联合奥沙利铂治疗广泛期小细胞肺癌(SCLC)的近期疗效和毒副反应。方法:62例广泛期SCLC患者随机分为2组。治疗组32例,伊立替康120mg/m2,静脉滴入,d1、d8;奥沙利铂130mg/m2,静脉滴入,d1;3周为1个周期。对照组30例,依托泊苷80mg/m2,静脉滴入,d1～d5;奥沙利铂130mg/m2,静脉滴入,d1;3周为1个周期。分别评价近期疗效、毒副反应和生存期。结果:治疗组与对照组有效率分别为68.75%(22/32)和46.67%(14/30),χ2=3.10,P=0.08。白细胞减少发生率治疗组(71.88%,23/32)少于对照组(100%,30/30),χ2=7.73,P=0.01。腹泻发生率治疗组(31.25%,10/32)高于对照组(10.00%,3/30),χ2=4.22,P=0.04。而二组1年生存率分别为62.50%和43.33%,χ2=2.28,P=0.13。结论:伊立替康联合奥沙利铂治疗广泛期SCLC相比依托泊苷联合奥沙利铂方案疗效提高,骨髓抑制反应轻,虽然腹泻发生率高,但能够耐受。 |
| 关 键 词： | 癌 小细胞肺 伊立替康 奥沙利铂 药物疗法 联合 毒副反应 |
Clinical study of irinotecan with oxaliplatin in treatment of extensive-stage small cell lung cancer |
|
| LI Hai-jin,DONG Liang,LI Ying,CHEN Ya-nan,SHANG Guan-min. Clinical study of irinotecan with oxaliplatin in treatment of extensive-stage small cell lung cancer[J]. Chinese Journal of Cancer Prevention and Treatment, 2010, 17(3) | |
| Authors: | LI Hai-jin DONG Liang LI Ying CHEN Ya-nan SHANG Guan-min |
| Affiliation: | LI+Hai-jin,DONG+Liang,LI+Ying,CHEN+Ya-nan,SHANG+Guan-min+Department+of+Oncology+Medicine,Shaoxing+Hospital,China+Medical+University,Shaoxing+312030,P.R.China |
| Abstract: | OBJECTIVE:To evaluate the effect and toxicity of the irinotecan plus oxaliplatin regimen in the treatment of patients with extensive-stage small cell lung cancer (SCLC).METHODS:A total of 62 patients with extensive-stage SCLC were randomized into 2 groups:a treatment group (32 cases) was treated with irinotecan 120 mg/m2 on day 1,8 and oxaliplatin 130 mg/m2 on day 1;and a control group (30 cases) was treated with etoposide 80 mg/m2 on day 1-5 and oxaliplatin 130 mg/m2 on day 1.Both of them were repeated eve... |
| Keywords: | carcinoma small-cell lung irinotecan oxaliplatin drug therapy combination toxicity |
| 本文献已被 CNKI 万方数据 等数据库收录！ | |